In such a scenario, the need for finding a vaccine is essential and also hard.
Based on the results from this phase 1/2a clinical trial that involved almost 400 healthy adults, a phase 2b trial has been initiated in southern Africa to determine the safety and efficacy of the HIV-1 vaccine candidate in 2,600 women at risk for acquiring HIV. This HIV-1 vaccine reportedly is the fifth concept to have reached this further in around forty years of the HIV pandemic.
However, there's a strong incentive for this vaccine to succeed.
But for this "mosaic" vaccine, scientists have developed a treatment made up of pieces of different HIV viruses. According to the study authors, the vaccine produced "robust (high levels of) immune responses" in the participants. Till date, this is the first out of five HIV vaccine concepts to have showed a positive response in nearly around 40 years of the HIV virus causing havoc among humans.More news: 138th ranked Gulbis shocks No. 4 Zverev at Wimbledon
Jean-Daniel Lelievre of France's Vaccine Research Institute said the vaccine was likely not the "definitive" version, but may represent "a phenomenal advance".
In addition to being well-tolerated by all the test subjects and inducing an immune response against HIV in humans, the vaccine provided 67% protection against infection from the simian-human immunodeficiency virus in the rhesus monkeys. However, because the mosaic vaccine attacks multiple strains of the virus, doctors would be able to administer it on a much broader scale, and it could potentially be a powerful weapon against HIV if all goes well. Thousands of people are still contracting HIV every year in the US - an estimated 38,500 people became infected with the virus in 2015 alone, according to the Centers for Disease Control and Prevention's latest statistics.
There may be a glimmer of hope in the fight to protect people from HIV-1, the most widespread type of the virus and the one that causes the most disease globally.
The results of the Imbokodo trial are expected in 2021/22.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding.More news: Starbucks to scrap plastic straws globally by 2020
As a part of this study, the HIV vaccine was tested on three hundred ninety-three people.
Creating an effective HIV-1 vaccine has been a huge challenge for researchers.
"I would say that we are pleased with these data so far, but we have to interpret the data cautiously".
More testing is now needed to determine if the immune response produced can prevent HIV infection in people.
The human trials participants for the study belonged from 12 clinics across the world, which includes east Africa, South Africa, the United States and Thailand. "We don't know whether protection in monkeys means there will be protection in humans".More news: 1 killed when helicopter crashes into Virginia homes